Leerink Partnrs Has Bullish Forecast for UTHR Q1 Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities researchers at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for United Therapeutics in a research note issued to investors on Friday, April 25th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will earn $6.48 per share for the quarter, up from their previous forecast of $6.32. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q2 2025 earnings at $7.20 EPS, Q3 2025 earnings at $8.08 EPS and Q4 2025 earnings at $7.82 EPS.

A number of other research analysts have also weighed in on UTHR. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a report on Monday, April 21st. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $390.17.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $5.43 during trading on Monday, reaching $297.66. The company had a trading volume of 174,029 shares, compared to its average volume of 447,797. The firm has a market capitalization of $13.37 billion, a price-to-earnings ratio of 13.07, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The stock's fifty day moving average price is $304.50 and its 200 day moving average price is $345.39. United Therapeutics has a fifty-two week low of $236.65 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the previous year, the business earned $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% on a year-over-year basis.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. Wealthfront Advisers LLC boosted its holdings in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $151,764,000. FMR LLC boosted its stake in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after buying an additional 393,777 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in United Therapeutics in the 1st quarter valued at $101,354,000. Finally, GAMMA Investing LLC boosted its stake in United Therapeutics by 29,415.2% in the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock worth $68,422,000 after purchasing an additional 221,202 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. The trade was a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,500 shares of company stock valued at $24,472,050 in the last quarter. Company insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.